09/04/2025
🚀 Invest in a Biotech Revolutionising Cancer Treatment
Kinled’s Private Client Division is now co-investing in a European biotech that's transforming precision oncology. Here’s why we’re backing it 👇
✅ Breakthrough Technology – A CE-marked platform that creates thousands of 3D replicas of a patient’s tumour to test drug responses in real time, allowing doctors to personalise therapy from day one.
✅ Direct-to-Patient Model – Redefining personalised medicine by bringing life-saving treatments closer to patients.
✅ Global Traction – Active in 20+ countries with 24 hospitals enrolled in its clinical programmes.
✅ Expanding Pipeline – Developing diagnostics for breast, lung, prostate, and skin cancers.
✅ World-Class Team – Led by experts with backgrounds at Roche, Novo Nordisk, Harvard Medical School, and more.
Why Now?
With three CE-marked diagnostic tests, this company has both scientific validation and commercial readiness. It’s positioned for rapid global expansion in a precision oncology market projected to exceed $120 billion globally.📈
The world is shifting towards personalised, data-driven cancer treatments, and this company is set to lead the way.
Interested in learning more?
Contact us today!